RxDoctor Payments DataLook up a doctor →

Brian Barry, MD

Neurology · Washington, DCNPI 1013335165

Payments from drug & device makers

$1,506,153in general payments, 2019–2025

Across 362 payments — averaging $4160.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • Biogen$182K
  • TG Therapeutics, Inc.$174K
  • E.r. Squibb & Sons, L.L.C.$37K
  • Genentech USA, Inc.$22K
  • Amgen$17K
  • plus $25K from 7 others
$1,664in research payments, 2019–2025

Across 2 payments — averaging $831.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$2K

What the payments were for

  • Consulting fees$39,29111%
  • Speaking & faculty fees$110,83431%
  • Grants$179,80050%
  • Travel & lodging$19,4115%
  • Food & beverage$9,6443%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis65$1,048,930
Biogen11$182,148
TG Therapeutics, Inc.84$173,818
E.r. Squibb & Sons, L.L.C.31$36,533
Genentech USA, Inc.37$22,286
Amgen(2 entities)66$17,485
Genentech, Inc.7$10,507
Bristol Myers Squibb31$8,427
EMD Serono, Inc.12$5,529
Sanofi13$393
AbbVie(2 entities)3$53
Amneal Pharmaceuticals LLC1$23
AstraZeneca1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,506,153 in reported general payments places this provider in the 95th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$93,607
Medicare patients
380
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab73$661,303
TecfideraDimethyl Fumarate24$243,336
VumerityDiroximel Fumarate11$95,218
Carbamazepine ErCarbamazepine30$3,310
Lamotrigine ErLamotrigine11$3,119
Levetiracetam67$2,411
Pregabalin65$2,386
Gabapentin93$1,993
Duloxetine Hcl71$1,817
Oxcarbazepine18$1,796
Lacosamide11$1,426
Baclofen31$955
Sumatriptan Succinate15$788
Donepezil Hcl47$388
Topiramate28$342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$182,148$338,55435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 neurology providers in District of Columbia.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →